- What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness
-
Sekiguchi , Hamano A, Kitagawa T, Ito K, Hirano K, Yamada K
- KMID: 2451019
- Blood Res.
- 2019 Jun;54(2):153-156.
- doi: 10.5045/br.2019.54.2.153
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent
-
Sekiguchi , Hamano A, Kitagawa T, Kurihara Y, Ito K, Kurimoto M, Watanabe K, Hirano K, Noto S, Yamada K, Takezako N
- KMID: 2451029
- Blood Res.
- 2018 Jun;53(2):117-122.
- doi: 10.5045/br.2018.53.2.117
BACKGROUND: Waldenström Macroglobulinemia (WM) is a rare subtype of indolent B-cell lymphoma, and prospective randomized studies on WM are scarce. The R-CHOP therapy [rituximab (R), cyclophosphamide, hydroxy-doxorubicin, vincristine, and prednisone]... -
- CITED
-
- Close
- SHARE
-
- Close
